Objective: Previous investigations have shown that the peroxisome proliferator activated receptor beta/delta (PPAR beta/delta)-angiopoietin-like protein 4 (ANGPTL4) pathways may be a new pharmacologic target for treatment of obesity. The present study was conducted to test the effect of phillyrin, a glucoside, on obesity in mice.& para;& para;Method: Fifty mice were randomly divided into 5 groups (n =10): control group (C57BL/6J mice), obese mice group, two groups of obese mice treated with phillyrin (15 or 45 mg/kg/day), one group of obese mice treated with PPAR beta/delta agonist GW0742 (3 m...
